Boeing vs. Rocket Lab: Which Aerospace Stock Is a Better Buy in 2026?

Rocket Lab is presented as the preferred 2026 aerospace investment, supported by 38% FY2025 revenue growth to $601.8 million, a record backlog above $2 billion, expanding launch cadence, and low leverage of 0.1x debt-to-equity. Boeing returned to profitability with FY2025 revenue of $89.5 billion, up 34.5%, and net income of $2.2 billion versus an $11.8 billion loss in FY2024, but it still faces operational, regulatory, defense-contract, and balance-sheet risks, including approximately 10.0x debt-to-equity and negative free cash flow of $1.9 billion. Rocket Lab remains loss-making, reporting a $198.2 million net loss and negative $321.8 million free cash flow as it funds Neutron development, making it a higher-growth but higher-volatility choice.

Analysis

The article’s central comparison is misleading for portfolio construction: BA is a leveraged execution and certification recovery, while RKLB is a duration-sensitive venture-style asset whose value rests on Neutron reaching commercial cadence. BA’s equity can re-rate materially on incremental production-rate normalization because fixed-cost absorption and delivery working-capital conversion are highly convex; however, that upside belongs behind creditors and depends on cash generation, not accounting profitability. The Spirit integration could improve supplier control over 12-24 months, but it also concentrates operational disruption and makes any further quality lapse more damaging.

RKLB’s headline growth does not yet establish unit economics capable of supporting a premium revenue multiple. Electron launch cadence alone is unlikely to justify the valuation; the relevant catalyst is credible Neutron schedule, customer deposits, and demonstrated gross-margin progression in Space Systems over the next 1-3 quarters. A Neutron delay would create a double hit—higher cash burn plus multiple compression—as investors reassess both terminal revenue and financing needs. The reported IRDM acquisition requires independent confirmation before it is incorporated into any thesis; if inaccurate or not formally announced, it is a material reliability failure in the source rather than an investable catalyst.

Near term, BA has the cleaner catalyst path if FAA production constraints ease and deliveries translate into free cash flow; RKLB has the stronger narrative but substantially greater downside from execution or a risk-off move in long-duration growth. The contrarian view is that BA’s recovery is more likely to be monetized through debt reduction than equity upside unless management proves sustained positive FCF, while RKLB’s optionality is already heavily capitalized. Neither warrants a directional position solely from this article.

Key Decisions for Investors

• Watch BA for a 1-3 month tactical long only after monthly delivery data and management guidance demonstrate sustained positive free cash flow; target a 15-20% re-rating on production normalization, with exit if 737/787 rate guidance is cut or FCF remains negative for two consecutive quarters.
• Avoid adding RKLB at current narrative-driven valuations until Neutron schedule, committed backlog quality, and quarterly cash burn are independently verified. Treat a Neutron schedule slip or cash use materially above guidance as a short/put-spread trigger rather than maintaining outright long exposure.
• Prefer a BA/LMT pair trade over BA/RKLB for aerospace exposure: long BA versus short LMT only if commercial-delivery momentum improves while defense fixed-price-charge risk persists. Use a 3-6 month horizon; stop out if BA’s operating cash-flow conversion fails to improve or LMT receives a material program award.
• Set an event-driven alert on IRDM: do not price in strategic value from the purported transaction without a definitive merger agreement, financing details, and regulatory timetable. If confirmed, assess exchange ratio and leverage before expressing a view; absent confirmation, exclude it from RKLB valuation work.